Press Release Summary:
- Stand-alone system is operated with on-board touch screen display and requires no external control unit
- Utilizes 35-100ml single use vessel that comes pre-sterilized
- Plug and play nature of the product provides efficiency and cost saving
Original Press Release:
Refine Technology to Showcase New CORe™ Mini BioReactor System at ESACT in Copenhagen May 5-8
New product offers a cost effective and bench space saving option for many cell culture applications.
Pine Brook, NJ - April 26, 2019. Refine Technology, LLC, most known for developing the award winning ATF™ System for cell perfusion, will be promoting its new CORe™ Mini BioReactor System at the upcoming European Society for Animal Cell Culture Meeting to be held in Copenhagen, Denmark from May 5-8. The CORe™ Mini BioReactor System is a compact, stand-alone bioreactor system with all of the features and performance of larger systems without compromising bench space or budget.
According to Chris Bartlett, Refine Technology’s Head of Sales and Marketing, “We have received a lot of early interest in this new technology in the fields of personalized medicine and stem cell culture applications. The compact size and single use, “plug and play” nature of the product provide efficiencies and cost savings not seen with larger systems. With global cell culture experts in attendance, ESACT is an ideal setting for us to begin to promote this new technology.”
The CORe™ Mini BioReactor System utilizes a 35-100ml single use vessel that comes pre-sterilized and utilizes external sensors for pH, DO and temperature. It is a stand-alone product that is operated with an on-board touch screen display and no need for an external control unit. It is sold with up to eight miniature peristaltic pumps for media addition and four gas control. The system costs much less than larger cell culture systems and the small working volume significantly reduces media costs.
About Refine Technology, LLC; Pine Brook, NJ: Refine Technology is based in Pine Brook, NJ and was founded in 1999 with a vision to develop and bring to market products in the field of animal cell culture. Following the successful sale of its award winning ATF™ system for cell perfusion product, Refine Technology has been developing innovative technologies for the bioprocess and cell culture market that address unmet needs and inefficiencies. Refine Technology, LLC currently has several products in its R&D pipeline that are expected to be released later in 2019. Further information may be found at: www.refinetech.com
Refine Technology, LLC
973-952-0002 ext. 302